Efficacy comparison of intravitreal injections of conbercept and ranibizumab for severe proliferative diabetic retinopathy

Published:August 25, 2018DOI:



      To determine the efficacy of preoperative intravitreal injections of conbercept (IVC) and ranibizumab (IVR) on postoperative best-corrected visual acuity (BCVA), vitreous hemorrhage (VH), and neovascular glaucoma (NVG) in a population with proliferative diabetic retinopathy (PDR) undergoing vitrectomy.


      Retrospective, cross-sectional study.


      386 patients with severe PDR (428 eyes).


      The patients who did not receive IVC or IVR were assigned to group A (125 eyes), the patients who received IVR (0.5 mg) were assigned to group B (146 eyes), and the patients who received IVC (0.5 mg) were assigned to group C (157 eyes).


      Both group B (p = 0.009) and group C (p = 0.002) had better postoperative BCVA than group A. Early postoperative VH occurred significantly less frequently in group B (22.60%; p = 0.007) and group C (12.10%; p < 0.001) than in group A (37.60%). Importantly, the incidences of postoperative NVG in group B (2.74%; p = 0.001) and group C (0.64%; p < 0.001) were both significantly less than that in group A (15.20%). However, there was no significant difference in the incidences of postoperative NVG between groups B and C (p = 0.325).


      The contribution of preoperative IVC to an improved BCVA for patients with severe PDR was better than that of IVR, and IVC decreased the risk of postoperative early VH. Pretreatment with IVC or IVR reduced the incidence of postoperative NVG based on the 24-month follow-up data.



      Déterminer l'efficacité des injections intravitréennes préopératoires de conbercept (CIV) et de ranibizumab (RIV) sur la meilleure acuité visuelle corrigée (MAVC), l'hémorragie vitréenne (HV) et le glaucome néovasculaire (GNV) postopératoires chez des sujets présentant une rétinopathie diabétique proliférante (RDP) qui devaient subir une vitrectomie.


      Étude transversale rétrospective.


      386 patients présentant une RDP grave (428 yeux).


      Les patients qui n'avaient reçu ni CIV ni RIV formaient le groupe A (125 yeux); ceux qui avaient reçu le RIV (0,5 mg) formaient le groupe B (146 yeux); et ceux qui avaient reçu le CIV (0,5 mg) formaient le groupe C (157 yeux).


      La MAVC postopératoire des sujets des groupes B (p = 0,009) et C (p = 0,002) était supérieure à celle des sujets du groupe A. Il s'est produit significativement moins de cas d'HV postopératoire précoce dans le groupe B (22,60 %; p = 0,007) et dans le groupe C (12,10 %; p < 0,001) que dans le groupe A (37,60 %). Fait important, l'incidence de GNV postopératoire était significativement moindre dans les groupes B (2,74 %; p = 0,001) et C (0,64 %; p < 0,001) comparativement au groupe A (15,20 %). Cela dit, on n'a enregistré aucune différence significative quant à l'incidence de GNV postopératoire entre les groupes B et C (p = 0,325).


      En présence de RDP grave, l'administration préopératoire de CIV a procuré une amélioration supérieure de la MAVC comparativement au RIV, sans compter que le CIV a réduit le risque d'HV postopératoire précoce. Selon les données du suivi à 24 mois, l'administration préalable de CIV ou de RIV a réduit l'incidence de GNV postopératoire.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sohn EH
        • van Dijk HW
        • Jiao C
        • et al.
        Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus.
        Proc Natl Acad Sci U S A. 2016; 113: E2655-E2664
        • Lu Q
        • Lu P
        • Chen W
        • Lu L
        • Zheng Z
        ANGPTL-4 induces diabetic retinal inflammation by activating Profilin-1.
        Exp Eye Res. 2017; 166: 140-150
        • Flynn HW
        • Chew EY
        • Simons BD
        • Barton FB
        • Remaley NA
        • Ferris FL
        Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. The Early Treatment Diabetic Retinopathy Study Research Group report number 17.
        Ophthalmology. 1992; 99: 1351-1357
        • Lu Q
        • Zou C
        • Cao H
        • et al.
        Preoperative intravitreal injection of ranibizumab for patients with severe proliferative diabetic retinopathy contributes to a decreased risk of postoperative neovascular glaucoma.
        Acta Ophthalmol. 2016; 94: 414-415
        • Ferenchak K
        • Duval R
        • Cohen JA
        • MacCumber MW
        Intravitreal bevacizumab for postoperative recurrent vitreous hemorrhage after vitrectomy for proliferative diabetic retinopathy.
        Retina. 2014; 34: 1177-1181
        • Elwan MM
        • Ghanem AA
        • Abousamra WA
        Outcome of a single intravitreal bevacizumab injection on the visual acuity and course of pars plana vitrectomy in proliferative diabetic retinopathy [Epub ahead of print].
        Curr Eye Res. 2013;
        • Su L
        • Ren X
        • Wei H
        • et al.
        Intravitreal conbercept (Kh902) for surgical treatment of severe proliferative diabetic retinopathy.
        Retina. 2016; 36: 938-943
        • Wang Q
        • Li T
        • Wu Z
        • et al.
        Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo.
        PloS One. 2013; 8: e70544
        • Yu DC
        • Lee JS
        • Yoo JY
        • et al.
        Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects.
        Molecular Therapy. 2012; 20: 938-947
        • Li H
        • Lei N
        • Zhang M
        • Li Y
        • Xiao H
        • Hao X
        Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit.
        Exp Eye Res. 2012; 97: 154-159
        • Wong TY
        • Liew G
        • Mitchell P
        Clinical update: new treatments for age-related macular degeneration.
        Lancet. 2007; 370: 204-206
        • Horsley MB
        • Mandava N
        • Maycotte MA
        • Kahook MY
        Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy.
        Am J Ophthalmol. 2010; 150: 558-561
        • Comyn O
        • Wickham L
        • Charteris DG
        • et al.
        Ranibizumab pretreatment in diabetic vitrectomy: a pilot randomised controlled trial (the RaDiVit study).
        Eye. 2017; 31: 1253-1258
        • Wells JA
        • Glassman AR
        • Ayala AR
        • et al.
        Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial.
        Ophthalmology. 2016; 123: 1351-1359
        • Sun Z
        • Zhou H
        • Lin B
        • et al.
        Efficacy and safety of intravitreal conbercept injections in macular edema secondary to retinal vein occlusion.
        Retina. 2017; 37: 1723-1730
        • Patel S
        • Sternberg Jr., P
        Diabetic retinopathy and antivascular endothelial growth factor agents.
        JAMA Ophthalmol. 2017;
        • Adamis AP
        • Miller JW
        • Bernal MT
        • et al.
        Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy.
        Am J Ophthalmol. 1994; 118: 445-450
        • Aiello LP
        • Avery RL
        • Arrigg PG
        • et al.
        Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
        N Engl J Med. 1994; 331: 1480-1487
        • Noma H
        • Funatsu H
        • Yamasaki M
        • et al.
        Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6.
        Am J Ophthalmol. 2005; 140: 256-261
        • Malik RA
        • Li C
        • Aziz W
        • et al.
        Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy.
        J Cell Mol Med. 2005; 9: 692-697
        • Lu Q
        • Zou W
        • Chen B
        • Zou C
        • Zhao M
        • Zheng Z
        ANGPTL-4 correlates with vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
        Graefes Arch Clin Exp Ophthalmol. 2016; 254: 1281-1288
        • Lu Q
        • Lu L
        • Chen W
        • Lu P
        Expression of angiopoietin-like protein 8 correlates with VEGF in patients with proliferative diabetic retinopathy.
        Graefes Arch Clin Exp Ophthalmol. 2017; 255: 1515-1523
        • Wakabayashi Y
        • Usui Y
        • Okunuki Y
        • et al.
        Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy.
        Invest Ophthalmol Vis Sci. 2012; 53: 6403-6410
        • Wang J
        • Chen S
        • Jiang F
        • et al.
        Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy.
        PloS One. 2014; 9e110531
        • Suzuki Y
        • Suzuki K
        • Yokoi Y
        • Miyagawa Y
        • Metoki T
        • Nakazawa M
        Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy.
        Retina. 2014; 34: 165-171
        • Jin E
        • Bai Y
        • Luo L
        • et al.
        Serum levels of vascular endothelial growth factor before and after intravitreal injection of ranibizumab or conbercept for neovascular age-related macular degeneration.
        Retina. 2017; 37: 971-977
        • Zhang M
        • Yu D
        • Yang C
        • et al.
        The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization.
        Pharm Res. 2009; 26: 204-210
        • Li F
        • Sun M
        • Guo J
        • Ma A
        • Zhao B
        Comparison of conbercept with ranibizumab for the treatment of macular edema secondary to branch retinal vein occlusion.
        Curr Eye Res. 2017; 42: 1174-1178
        • Qu J
        • Cheng Y
        • Li X
        • Yu L
        • Ke X
        Efficacy of intravitreal injection of conbercept in polypoidal choroidal vasculopathy: subgroup analysis of the Aurora Study.
        Retina. 2016; 36: 926-937
        • Li X
        • Xu G
        • Wang Y
        • et al.
        Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: Aurora Study.
        Ophthalmology. 2014; 121: 1740-1747